Julian Harrison
Stock Analyst at BTIG
(2.03)
# 3,018
Out of 4,915 analysts
38
Total ratings
40.62%
Success rate
-3.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Buy | $24 → $25 | $11.12 | +124.82% | 2 | Jun 27, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $7.89 | +406.97% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $12.69 | +230.97% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $14.33 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $24.55 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.96 | +359.18% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.53 | +422.88% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $0.36 | +2,104.46% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $17.52 | +248.17% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $5.95 | +152.10% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $25 | $18.69 | +33.76% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $53.86 | -5.31% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $71.77 | -40.09% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $16.97 | +135.71% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $38.26 | +12.39% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $3.69 | +8.55% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.88 | +16,945.45% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $50.28 | -28.40% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $274.70 | - | 2 | Feb 11, 2022 |
Theravance Biopharma
Jun 27, 2025
Maintains: Buy
Price Target: $24 → $25
Current: $11.12
Upside: +124.82%
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $7.89
Upside: +406.97%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $12.69
Upside: +230.97%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.33
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $24.55
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.96
Upside: +359.18%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.53
Upside: +422.88%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.36
Upside: +2,104.46%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $17.52
Upside: +248.17%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.95
Upside: +152.10%
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $18.69
Upside: +33.76%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $53.86
Upside: -5.31%
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $71.77
Upside: -40.09%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $16.97
Upside: +135.71%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $38.26
Upside: +12.39%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $3.69
Upside: +8.55%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.88
Upside: +16,945.45%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $50.28
Upside: -28.40%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $274.70
Upside: -